BX-912 is primarily used as a potent and selective inhibitor of the Akt signaling pathway, which plays a critical role in cell survival, proliferation, and metabolism. Due to its ability to suppress Akt activation, BX-912 has gained interest in cancer research, particularly in studies targeting tumors with hyperactivated Akt pathways. It has demonstrated anti-tumor effects in various preclinical models by inducing apoptosis and reducing cell viability in cancer cell lines. Researchers also utilize BX-912 to investigate downstream effects of Akt inhibition, including modulation of mTOR and GSK-3β signaling. Its application extends to studying drug resistance mechanisms and evaluating combination therapies with other anticancer agents. BX-912 is mainly employed in laboratory and experimental settings, contributing to the development of targeted cancer treatments.